DJIA 17,566.43 -31.77 -0.18%
NASDAQ 5,111.55 -3.84 -0.07%
S&P 500 2,095.78 -2.26 -0.11%
market minute promo

AstraZeneca plc (ADR) (NYSE: AZN)

34.37 0.43 (1.27%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

AZN $34.37 1.27%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $34.22
Previous Close $33.94
Daily Range $34.18 - $34.47
52-Week Range $31.61 - $38.12
Market Cap $86.9B
P/E Ratio 33.27
Dividend (Yield) $0.90 (4.1%)
Ex-Dividend Date
Dividend Pay Date
08/12/15
09/14/15
Volume 1,234,181
Average Daily Volume 2,816,681
Current FY EPS $2.13

Sector

Healthcare

Industry

Drug Makers

AstraZeneca plc (ADR) (AZN) Description

The Company discovers, develops, manufactures and markets prescription pharmaceuticals for important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation. Website: http://www.astrazeneca.com/

News & Commentary

Are These 2 Big Pharmas Really Buyout Candidates?

AstraZeneca and Bristol-Myers Squibb's names have both repeatedly surfaced on the buyout rumor mill this year. Do these rumors have legs, or are they nothing more than speculation?

A Post-Earnings Review Of Amgen, With Discussion Of The Repatha Launch

Premarket Biotech Digest: Gilead HIV, Eliquis Trial Errors, Clinical Trial Phases

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antis

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease

AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs for Cardiovascular, Meta

AstraZeneca, Isis Pharmaceuticals to Collaborate to Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases

Healthcare: 9.6% More Net Gains From 5 Highest Yield, Lowest Priced July 29 Dogs

10 Top Healthcare Dividend Dogs: 11% To 47.9% Upsides And 12.1% To 48.3% Net Gains As Of July 29

Healthcare Dividend Dogs: 3% To 10% Yields From Top 10 As Of July 29

Alkermes' Reports Wider Q2 Loss, Increases Guidance - Analyst Blog

AstraZeneca Beats on Q2 Earnings, Revises Revenue View - Analyst Blog

AstraZeneca Beats on Q2 Earnings, Revises Revenue View - Analyst Blog

AstraZeneca (AZN) Earnings Report: Q2 2015 Conference Call Transcript

See More AZN News...

AZN's Top Competitors

AZN $34.37 (1.27%)
Current stock: AZN
JNJ $99.89 (-0.13%)
Current stock: JNJ
NVS $103.68 (-0.65%)
Current stock: NVS
RHHBY $35.97 (0.06%)
Current stock: RHHBY